<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="46884"><DrugName>Prolastin</DrugName><DrugNamesKey><Name id="42806914">Prolastin</Name><Name id="42915994">Prolastin-C</Name><Name id="43130858">Prolastin-C Liquid</Name><Name id="43080651">Prolastina</Name><Name id="43080652">Pulmolast</Name></DrugNamesKey><DrugSynonyms><Name><Value>Prolastin</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>alpha-1 antitrypsin, Bayer</Value></Name><Name><Value>alpha-1 proteinase inhibitor (human), Bayer</Value></Name><Name><Value>alpha-1 antitrypsin, Talecris/Crucell</Value></Name><Name><Value>Prolastin-C</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>TAL-6004</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>alpha-1 antitrypsin, Grifols /Crucell</Value></Name><Name><Value>BAYx-5747</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>BAY-105233</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>TAL-0500007</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Alpha-1 MP</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Prolastina</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Pulmolast</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Prolastin-C Liquid</Value><Types><Type>Trade Name</Type></Types></Name></DrugSynonyms><CompanyOriginator id="14455">Bayer AG</CompanyOriginator><CompaniesPrimary><Company id="1013827">Grifols Inc</Company><Company id="16581">Grifols SA</Company><Company id="15381">Chiesi Farmaceutici SpA</Company></CompaniesPrimary><CompaniesSecondary><Company id="14455">Bayer AG</Company></CompaniesSecondary><CrossReferences><SourceEntity id="46884" type="Drug"><TargetEntity id="660163" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="1013827" type="Company"><TargetEntity id="4297207566" type="organizationId">Talecris Biotherapeutics Holdings Corp</TargetEntity></SourceEntity><SourceEntity id="14455" type="Company"><TargetEntity id="4295869217" type="organizationId">Bayer AG</TargetEntity></SourceEntity><SourceEntity id="15381" type="Company"><TargetEntity id="4296558863" type="organizationId">Chiesi Farmaceutici SpA</TargetEntity></SourceEntity><SourceEntity id="16581" type="Company"><TargetEntity id="4295889506" type="organizationId">Grifols SA</TargetEntity></SourceEntity><SourceEntity id="1298" type="ciIndication"><TargetEntity id="E88.01" type="ICD10"></TargetEntity><TargetEntity id="273.4" type="ICD9"></TargetEntity><TargetEntity id="10001806" type="MEDDRA"></TargetEntity><TargetEntity id="D019896" type="MeSH"></TargetEntity><TargetEntity id="60" type="ORPHANET"></TargetEntity><TargetEntity id="-582324492" type="omicsDisease"></TargetEntity><TargetEntity id="2511" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="158" type="ciIndication"><TargetEntity id="B20" type="ICD10"></TargetEntity><TargetEntity id="042" type="ICD9"></TargetEntity><TargetEntity id="10020161" type="MEDDRA"></TargetEntity><TargetEntity id="D015658" type="MeSH"></TargetEntity><TargetEntity id="-841965209" type="omicsDisease"></TargetEntity><TargetEntity id="862" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="836" type="ciIndication"><TargetEntity id="E10" type="ICD10"></TargetEntity><TargetEntity id="10067584" type="MEDDRA"></TargetEntity><TargetEntity id="D003922" type="MeSH"></TargetEntity><TargetEntity id="-686743471" type="omicsDisease"></TargetEntity><TargetEntity id="507" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1594" type="Action"><TargetEntity id="2409" type="Mechanism">Carbon Monoxide-Releasing Agents</TargetEntity><TargetEntity id="5353" type="Mechanism">Drugs Targeting Clostridium tetani Proteins</TargetEntity><TargetEntity id="5306" type="Mechanism">Drugs Targeting Mycobacterium tuberculosis Proteins</TargetEntity><TargetEntity id="4493" type="Mechanism">Drugs Targeting Campylobacter jejuni Proteins</TargetEntity><TargetEntity id="3697" type="Mechanism">Drugs Targeting Escherichia coli Proteins</TargetEntity><TargetEntity id="3994" type="Mechanism">Drugs Targeting Pseudomonas aeruginosa Proteins</TargetEntity><TargetEntity id="5053" type="Mechanism">Anti-Diphtheria Toxin</TargetEntity><TargetEntity id="4563" type="Mechanism">Anti-Diphteria Toxin (Corynebacterium diphtheriae)</TargetEntity><TargetEntity id="1060" type="Mechanism">Efflux Pump (Bacterial) Inhibitors</TargetEntity><TargetEntity id="4457" type="Mechanism">Drugs Targeting Staphylococcus aureus Proteins</TargetEntity><TargetEntity id="3878" type="Mechanism">Drugs Targeting Bacterial Chaperones</TargetEntity></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity></SourceEntity><SourceEntity id="349" type="Action"><TargetEntity id="861" type="Mechanism">Serine Protease Inhibitors</TargetEntity><TargetEntity id="4799" type="Mechanism">Convertase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="399" type="Action"><TargetEntity id="884" type="Mechanism">Glucose Lowering Agents</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Alpha-1 antitrypsin deficiency - US - Feb-1988</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><Indication id="836">Insulin dependent diabetes</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="158">HIV infection</Indication></IndicationsSecondary><ActionsPrimary><Action id="51">Alpha 1 proteinase inhibitor</Action><Action id="349">Serine protease inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="1594">Antibacterial</Action><Action id="399">Hypoglycemic agent</Action><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="898">Formulation powder</Technology><Technology id="806">Weekly dosing</Technology><Technology id="80">Peptide</Technology><Technology id="740">Infusion</Technology><Technology id="750">Freeze drying</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="648">Intravenous formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>J1</Code><Name>SYSTEMIC ANTIBACTERIALS</Name></Ephmra><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2019-04-01T11:47:49.000Z</LastModificationDate><ChangeDateLast>2018-11-13T00:00:00.000Z</ChangeDateLast><AddedDate>2003-09-24T14:55:18.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Alpha-1 proteinase inhibitor (Prolastin; Prolastin-C; Prolastin-C Liquid; Pulmolast; Prolastina; BAYx-5747; BAY-105233; TAL-0500007; Alpha-1 MP; TAL-6004) is a sterile, stable, lyophilized, intravenous preparation of purified plasma-derived human alpha-1 proteinase inhibitor (A1PI; alpha-1 antitrypsin)  and serine protease inhibitor [&lt;ulink linkID="1073662" linkType="Reference"&gt;1073662&lt;/ulink&gt;], [&lt;ulink linkID="1531888" linkType="Reference"&gt;1531888&lt;/ulink&gt;]. It was developed and previously launched by &lt;ulink linkID="14455" linkType="Company"&gt;Bayer AG&lt;/ulink&gt;, and is now marketed by &lt;ulink linkID="1013827" linkType="Company"&gt;&lt;/ulink&gt;&lt;ulink linkID="1013827" linkType="Company"&gt;Grifols Inc&lt;/ulink&gt;, previously known as Talecris Biotherapeutics, a subsidiary of &lt;ulink linkID="16581" linkType="Company"&gt;Grifols SA&lt;/ulink&gt;. The product is indicated as a chronic replacement therapy in patients with congenital alpha-1antitrypsin deficiency and clinically demonstrable panacinar emphysema [&lt;ulink linkID="506121" linkType="Reference"&gt;506121&lt;/ulink&gt;], [&lt;ulink linkID="507038" linkType="Reference"&gt;507038&lt;/ulink&gt;], [&lt;ulink linkID="590985" linkType="Reference"&gt;590985&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Prolastin was initially launched worldwide by Bayer in February 1988 [&lt;ulink linkID="1073662" linkType="Reference"&gt;1073662&lt;/ulink&gt;]. In October 2009, a concentrated version of the drug, Prolastin-C (TAL-6004),  was approved by the FDA [&lt;ulink linkID="1050391" linkType="Reference"&gt;1050391&lt;/ulink&gt;]; launch took place in March 2010 [&lt;ulink linkID="1119712" linkType="Reference"&gt;1119712&lt;/ulink&gt;]. In 2017, the FDA approved a ready-to-infuse liquid formulation of the product as Prolastin-C Liquid [&lt;ulink linkID="2015861" linkType="Reference"&gt;2015861&lt;/ulink&gt;]. A phase I/II trial of Prolastin C was initiated in Japan in November 2016 [&lt;ulink linkID="2092593" linkType="Reference"&gt;2092593&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Development for other indications is ongoing. Grifols is also investigating the drug for the treatment of type 1 diabetes. In March 2014, a phase II trial was initiated in the US; in June 2017, the study was terminated;  in April 2018, data were reported [&lt;ulink linkID="1543468" linkType="Reference"&gt;1543468&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Prolastin-C was previously being developed for the potential treatment of HIV infection. In April 2012, a  phase II/III trial of Prolastin-C was initiated in the US in patients  with HIV infection; however, by December 2014, the trial had been terminated due to potential non compliance with protocol  [&lt;ulink linkID="1441799" linkType="Reference"&gt;1441799&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;Patent coverage (&lt;ulink linkID="IN1108801" linkType="Patent"&gt;US-04379087&lt;/ulink&gt;) expired in June 2002.&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;&lt;subtitle&gt;Prolastin&lt;/subtitle&gt;The drug was first approved in the US in December 1987, and launched in February 1988 [&lt;ulink linkID="1073662" linkType="Reference"&gt;1073662&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Prolastin-C&lt;/subtitle&gt;In October 2009, Prolastin-C was approved by the FDA [&lt;ulink linkID="1050391" linkType="Reference"&gt;1050391&lt;/ulink&gt;]; launch took place in March 2010 [&lt;ulink linkID="1119712" linkType="Reference"&gt;1119712&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2015, the FDA granted Prolastin-C Orphan status for the treatment of  type 1 diabetes mellitus patients with residual beta-cell function [&lt;ulink linkID="1639383" linkType="Reference"&gt;1639383&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Prolastin-C Liquid&lt;/subtitle&gt;In 2017, the FDA approved a ready-to-infuse liquid formulation of the product [&lt;ulink linkID="2015861" linkType="Reference"&gt;2015861&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;&lt;subtitle&gt;Prolastin&lt;/subtitle&gt;In October 2006, Prolastin was approved in Spain [&lt;ulink linkID="1362577" linkType="Reference"&gt;1362577&lt;/ulink&gt;]. In November 2006, the drug was launched in Portugal [&lt;ulink linkID="1366197" linkType="Reference"&gt;1366197&lt;/ulink&gt;]; at that time,   the drug was approved in the Netherlands [&lt;ulink linkID="1432109" linkType="Reference"&gt;1432109&lt;/ulink&gt;]. In January 2007, Prolastin was approved  in Ireland [&lt;ulink linkID="1401215" linkType="Reference"&gt;1401215&lt;/ulink&gt;]. In October 2008, the drug was approved in Greece [&lt;ulink linkID="1441275" linkType="Reference"&gt;1441275&lt;/ulink&gt;] and was subsequently launched [&lt;ulink linkID="1438015" linkType="Reference"&gt;1438015&lt;/ulink&gt;].  By May 2012, licensee &lt;ulink linkID="15381" linkType="Company"&gt;Chiesi Farmaceutici&lt;/ulink&gt; had launched Prolastin in Austria [&lt;ulink linkID="1336159" linkType="Reference"&gt;1336159&lt;/ulink&gt;]. By February 2019, the drug had been launched in the Netherlands [&lt;ulink linkID="2136481" linkType="Reference"&gt;2136481&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2012, the drug was launched in Switzerland [&lt;ulink linkID="1602390" linkType="Reference"&gt;1602390&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Prolastin-C&lt;/subtitle&gt;In 2013, Grifols initiated clinical trials in Europe to gain approval of Prolastin-C  [&lt;ulink linkID="1749555" linkType="Reference"&gt;1749555&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In March 2016, Grifols' human alpha-1-proteinase inhibitor was granted Orphan designation in Japan for the treatment of severe alpha-1-antitrypsin deficiency with COPD [&lt;ulink linkID="1752002" linkType="Reference"&gt;1752002&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;&lt;subtitle&gt;Prolastin-C&lt;/subtitle&gt;In February 2010, Prolastin-C was approved in Canada [&lt;ulink linkID="1075893" linkType="Reference"&gt;1075893&lt;/ulink&gt;];  launch was expected in Canada in 3Q10 [&lt;ulink linkID="1119712" linkType="Reference"&gt;1119712&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;&lt;subtitle&gt;Prolastin&lt;/subtitle&gt;By May 2013, Prolastin had been approved in certain South American countries [&lt;ulink linkID="1426101" linkType="Reference"&gt;1426101&lt;/ulink&gt;]. By February 2018, the drug had been launched in Argentina [&lt;ulink linkID="2136484" linkType="Reference"&gt;2136484&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Prolastin-C&lt;/subtitle&gt;By May 2013, Prolastin-C had been approved in  Colombia [&lt;ulink linkID="1426101" linkType="Reference"&gt;1426101&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2013, Prolastin-C had been approved in Argentina  [&lt;ulink linkID="1426101" linkType="Reference"&gt;1426101&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;&lt;subtitle&gt;Prolastin-C&lt;/subtitle&gt;In November 2016, the drug was approved in Australia to increase serum alpha1-PI levels in adults with congenital deficiency of alpha-1 antitrypsin and with clinically significant emphysema [&lt;ulink linkID="1877707" linkType="Reference"&gt;1877707&lt;/ulink&gt;]. By April 2016, the drug had been launched in Australia [&lt;ulink linkID="2136480" linkType="Reference"&gt;2136480&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;&lt;subtitle&gt;Prolastin&lt;/subtitle&gt;In September 2006,  safety data were presented at the 2006 Annual Congress of the European Respiratory Society in Munich, Germany. Data, collected since the original approval of Prolastin in 1987, demonstrated that the drug was well tolerated with respect to drug interactions, overdose and abuse potential [&lt;ulink linkID="688446" linkType="Reference"&gt;688446&lt;/ulink&gt;]. Data were also presented demonstrating that the Prolastin manufacturing process significantly removes or inactivates key viruses as well as pathogenic prions such as those associated with variant Creutzfeldt-Jakob disease [&lt;ulink linkID="688447" linkType="Reference"&gt;688447&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Prolastin C&lt;/subtitle&gt;In November 2013, a randomized, double-blind, placebo controlled study (&lt;ulink linkID="161238" linkType="Protocol"&gt;NCT01983241&lt;/ulink&gt;; SPARTA; GTi1201) was initiated in the US, Europe, Canada, Australia, New Zealand and Brazil to assess the efficacy and safety of two separate dose regimens of prolastin (60 and 120 mg/kg) versus placebo for 3 years in patients (expected n = 339) with pulmonary emphysema in alpha-1 antitrypsin deficiency. The primary endpoint was the change from baseline in whole lung PD15. In October 2018 the study was expected to complete in November 2023 [&lt;ulink linkID="2090125" linkType="Reference"&gt;2090125&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2013, data from the multidose, pharmacokinetic, SPARK trial of Prolastin-C were presented at the annual meeting of the American Thoracic Society in Philadelphia, PA. Weekly infusions of 120 mg/kg Prolastin C were shown to increase serum A1PI concentrations to proportionately higher levels than weekly infusions of 60 mg/kg. The 120 mg/kg dose also provided closer-to-physiologic A1PI concentrations compared with 60 mg/kg [&lt;ulink linkID="1426101" linkType="Reference"&gt;1426101&lt;/ulink&gt;].&lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Prolastin&lt;/subtitle&gt;In May 2006, a non-randomized, open-label, single-group, multi-center phase III trial (&lt;ulink linkID="174870" linkType="Protocol"&gt;NCT00301366&lt;/ulink&gt;; 11815) to evaluate the safety and tolerability of the drug was initiated in the US, UK and Poland  in Alpha-1 antitrypsin deficiency subjects (n = 38). The trial was completed in March 2007 [&lt;ulink linkID="1531888" linkType="Reference"&gt;1531888&lt;/ulink&gt;]. In November 2014, data were presented at the AHA Scientific Sessions in Chicago, IL.											 A single administration of plasma-derived AAT, prolastin C, is well tolerated, significantly inhibited the acute inflammatory response. Single death was reported in the prolastin C group  and none had new onset heart failure or recurrent myocardial infarction [&lt;ulink linkID="1614688" linkType="Reference"&gt;1614688&lt;/ulink&gt;], [&lt;ulink linkID="1614092" linkType="Reference"&gt;1614092&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2016, a multicenter, open-label phase I/II trial (&lt;ulink linkID="268617" linkType="Protocol"&gt;NCT02870309&lt;/ulink&gt;; GTI1401) to evaluate the safety and pharmacokinetics of alpha-1 MP in patients (expected n = 3) with alpha1-antitrypsin deficiency, was initiated in Japan. In March 2017, the study was completed [&lt;ulink linkID="1790160" linkType="Reference"&gt;1790160&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In clinical studies, 23 patients with the PiZZ variant of alpha-1 antitrypsin deficiency and documented lung destruction disease participated in a study of acute and/or chronic replacement therapy with Prolastin. With acute delivery, the mean in vivo recovery of alpha-1 PI was 4.2 mg/dL per mg/kg body weight administered. With chronic administration once weekly for 26 weeks, blood levels of alpha-1 PI were maintained above 80 mg/dL. Within weeks, broncoalveolar lavage studies demonstrated significantly increased levels of alpha-1 PI and functional antineutrophil elastase capacity in the epithelial lining fluid as compared to before treatment [&lt;ulink linkID="507038" linkType="Reference"&gt;507038&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Prolastin-C&lt;/subtitle&gt;&lt;subtitle&gt;Alpha1-antitrypsin deficiency&lt;/subtitle&gt;In November 2016, an interventional, multi-center, open-label, single group assigned,  phase I/II study (&lt;ulink linkID="268626" linkType="Protocol"&gt;NCT02870348&lt;/ulink&gt;; GTI1401-OLE) was initiated in Japan, to evaluate the long-term safety of weekly intravenous infusions of alpha1-proteinase inhibitor (human) in patients with (n = 3) alpha-1 antitrypsin deficiency.  At that time, the trial was expected to complete in March 2020 [&lt;ulink linkID="2092593" linkType="Reference"&gt;2092593&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2014, a multi-center, randomized, double-blind, crossover, phase II/III study (&lt;ulink linkID="215263" linkType="Protocol"&gt;NCT02282527&lt;/ulink&gt;; GTI1402) began in the US to evaluate the safety, immunogenicity, pharmacokinetics and bioequivalency of liquid Prolastin-C compared with the previous formulation of Prolastin-C in patients (n = 32) with alpha-1 antitrypsin deficiency. The primary endpoint was AUC from 0 to 7 days. The study was complete in January 2016 [&lt;ulink linkID="2090140" linkType="Reference"&gt;2090140&lt;/ulink&gt;].  In May 2017, data were presented at the 2017 ATS International Conference in Washington DC. Patients received weekly iv infusion of 60 mg/kg liquid Prolastin-C or Prolastin-C for 8 weeks and later crossed over to the alternate therapy for 8 weeks. For liquid alpha1-proteinase inhibitor and Prolastin-C, mean alpha1-proteinase inhibitor concentration versus time curves were superimposable;  the mean AUC(0 to 7 days) was 203.2 and 198.4 mg.h/ml, respectively; and the geometric least squares mean ratio of AUC (0 to 7 days) was 1.05 indicating bioequivalence between both formulations. Liquid Alpha1-proteinase inhibitor was safe, well tolerated and comparable to Prolastin-C [&lt;ulink linkID="1929452" linkType="Reference"&gt;1929452&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2009, data from clinical trials comparing Prolastin and Prolastin-C had been reported. Adverse events were reported at a rate of 0.117 and 0.078 per infusion for Prolastin-C and Prolastin, respectively [&lt;ulink linkID="1050391" linkType="Reference"&gt;1050391&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Prolastin-C was tested in 62 patients in two clinical studies. In one study, 32 patients were treated with iv weekly Prolastin-C; half were new to therapy and half were previously being treated with Prolastin. 84.2% had the PiZZ genotype. Prolastin-C was pharmacokinetically equivalent to Prolastin, and equally effective at raising AAT levels in the blood [&lt;ulink linkID="1050391" linkType="Reference"&gt;1050391&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;HIV infection&lt;/subtitle&gt;In April 2012, a 	, double-blind, parallel-group, safety/efficacy phase II/III trial (&lt;ulink linkID="99362" linkType="Protocol"&gt;NCT01731691&lt;/ulink&gt;; Prolastin-C in HIV disease) was initiated in the US in patients (expected n = 20) with HIV infection. The trial was expected to complete in May 2013. However, by December 2014, the trial had been terminated due to potential non compliance with protocol [&lt;ulink linkID="1441799" linkType="Reference"&gt;1441799&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Type-1 diabetes&lt;/subtitle&gt;In March 2014, a randomized, parallel assigned, double blind, partial-blinded, placebo-controlled, phase II trial (&lt;ulink linkID="178605" linkType="Protocol"&gt;NCT02093221&lt;/ulink&gt;; GTI1302) was initiated in the US in patients (n = 76) with new-onset type 1 diabetes mellitus to determine the safety and efficacy of Prolastin-C. The primary endpoint was the change from baseline in C-peptide concentration during mixed meal tolerance test (MMTMT)  with high protein energy drink. In June 2017, the study was terminated (week 104) as primary endpoint results would be unaffected by follow-up data. In April 2018, data were reported. Change from baseline in C-peptide concentration at week 26 was -32.357 and -21.5787 for 180 and 90 mg/kg dose respectively. At week 13, the changes were -25.171 and -34.393, compared with -16.909 in the placebo group    [&lt;ulink linkID="1543468" linkType="Reference"&gt;1543468&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In May 2018, preclinical data were presented at the 2018 ATS International Conference in San Diego, CA. In lyophilized alpha-1 proteinase inhibitor (A1PI; 200 mg/kg) versus liquid A1PI (200 mg/kg), AUC last (134 versus 137 mg.h/ml), AUC inf (147 versus 150 mg.h.ml), t1/2 (46.3 versus 46.9 h), cl (1.36 versus 1.33 ml/h/kg), Vz (91.2 versus 89.9 ml/kg) were observed. Safety investigation demonstrated good tolerability, with no test article-related changes in mortality, clinical signs, clinical pathology, body weight, food consumption, urinalysis or coagulation parameters. In rabbits, the neoantigenicity immunization protocol enhanced robust immune responses as indicated by antibody titers above 300,000 to human A1PI. It was observed that antibody titers from all rabbits were reduced following immunodepletion with lyophilized A1PI [&lt;ulink linkID="2035150" linkType="Reference"&gt;2035150&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2014, preclinical data were presented at the 2014 ATS International Conference in San Diego, CA. Pseudomonas aeruginosa (PA) infection increased the IL-8 levels which were significantly reduced by alpha1-antitrypsin and also, reduced IL-8 levels in the absence of PA infection. Overall, the absolute reduction of IL-8 levels was observed in PA infected cell lines.  Alpha1-antitrypsin exhibited an anti-inflammatory effect on airway epithelial cells during PA infection [&lt;ulink linkID="1557141" linkType="Reference"&gt;1557141&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In 2017, the Grifol's Diagnostic Division obtained FDA approval for a new genetic test for alpha-1 antitrypsin aimed at improving the diagnosis of its deficiency [&lt;ulink linkID="2015861" linkType="Reference"&gt;2015861&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15381">Chiesi Farmaceutici SpA</Company><Country id="AT">Austria</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-05-31T00:00:00.000Z</StatusDate><Source id="1336159" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013827">Grifols Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-04-01T00:00:00.000Z</StatusDate><Source id="590985" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013827">Grifols Inc</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-09-01T00:00:00.000Z</StatusDate><Source id="1602390" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013827">Grifols Inc</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-11-13T00:00:00.000Z</StatusDate><Source id="1366197" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013827">Grifols Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-04-01T00:00:00.000Z</StatusDate><Source id="590985" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16581">Grifols SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><Source id="1362577" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013827">Grifols Inc</Company><Country id="GR">Greece</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><Source id="1438015" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013827">Grifols Inc</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><Source id="1401215" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013827">Grifols Inc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-02-12T00:00:00.000Z</StatusDate><Source id="2136481" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013827">Grifols Inc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-06T00:00:00.000Z</StatusDate><Source id="2136484" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013827">Grifols Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-02-17T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013827">Grifols Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-11-15T00:00:00.000Z</StatusDate><Source id="2136480" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013827">Grifols Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="836">Insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-31T00:00:00.000Z</StatusDate><Source id="1543468" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013827">Grifols Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-08-23T00:00:00.000Z</StatusDate><Source id="1790160" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013827">Grifols Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-12-18T00:00:00.000Z</StatusDate><Source id="1441799" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-04-01T00:00:00.000Z</StatusDate><Source id="590985" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1013827">Grifols Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-02-17T00:00:00.000Z</StatusDate><Source id="1075893" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1988-02-29T00:00:00.000Z</StatusDate><Source id="1073662" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-04-01T00:00:00.000Z</StatusDate><Source id="590985" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16581">Grifols SA</Company><Country id="ES">Spain</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-10-18T00:00:00.000Z</StatusDate><Source id="1362577" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013827">Grifols Inc</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-01-05T00:00:00.000Z</StatusDate><Source id="1401215" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013827">Grifols Inc</Company><Country id="GR">Greece</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-10-17T00:00:00.000Z</StatusDate><Source id="1441275" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013827">Grifols Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="836">Insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-31T00:00:00.000Z</StatusDate><Source id="1543468" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013827">Grifols Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-04-30T00:00:00.000Z</StatusDate><Source id="1441799" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013827">Grifols Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-03-16T00:00:00.000Z</StatusDate><Source id="1752002" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013827">Grifols Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-11-10T00:00:00.000Z</StatusDate><Source id="1877707" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013827">Grifols Inc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-11-28T00:00:00.000Z</StatusDate><Source id="1432109" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013827">Grifols Inc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-05-22T00:00:00.000Z</StatusDate><Source id="1426101" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013827">Grifols Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-05-22T00:00:00.000Z</StatusDate><Source id="1426101" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1987-12-31T00:00:00.000Z</StatusDate><Source id="1073662" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="16581">Grifols SA</OwnerCompany><Country id="JP">Japan</Country><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><AwardedIndication>Severe alpha1-antitrypsin deficiency with COPD</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-03-16T00:00:00.000Z</MileStoneDate><Source id="1752002" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1013827">Grifols Inc</OwnerCompany><Country id="US">US</Country><Indication id="836">Insulin dependent diabetes</Indication><AwardedIndication>Treatment of Type 1 diabetes mellitus patients with residual beta-cell function.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-03T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1013827">Grifols Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><AwardedIndication>Treatment of emphysema secondary to congenital alpha-1-antitrypsin deficiency</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="9">Withdrawn</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-12-01T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1013827">Grifols Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><AwardedIndication>Treatment of emphysema secondary to congenital alpha-1-antitrypsin deficiency</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-03-31T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1013827">Grifols Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><AwardedIndication>Treatment of emphysema secondary to congenital alpha-1-antitrypsin deficiency</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-05-30T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1013827">Grifols Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><AwardedIndication>Treatment of emphysema secondary to congenital alpha-1-antitrypsin deficiency</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-04-10T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="14455">Bayer AG</OwnerCompany><Country id="US">US</Country><Indication id="1298">Alpha-1 antitrypsin deficiency</Indication><AwardedIndication>For replacement therapy in the alpha-1-proteinase inhibitor congenital deficiency state.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1984-12-07T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00117"><Name>Alpha-1 proteinase</Name><SwissprotNumbers></SwissprotNumbers></Target><Target id="PTGT-01722"><Name>Serine protease</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>10 references added [&lt;ulink url="utility.reference?i_reference_id=2100710" linkType="reference" linkID="2100710"&gt;2100710&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1980145" linkType="reference" linkID="1980145"&gt;1980145&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1089536" linkType="reference" linkID="1089536"&gt;1089536&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1120741" linkType="reference" linkID="1120741"&gt;1120741&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1901827" linkType="reference" linkID="1901827"&gt;1901827&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1590621" linkType="reference" linkID="1590621"&gt;1590621&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1652545" linkType="reference" linkID="1652545"&gt;1652545&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2090176" linkType="reference" linkID="2090176"&gt;2090176&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1557954" linkType="reference" linkID="1557954"&gt;1557954&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1993109" linkType="reference" linkID="1993109"&gt;1993109&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1036101">Inamed Research</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1102379">Alpha-1 Biologics Corp</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1164370">Centric Health resources Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="14455">Bayer AG</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="15381">Chiesi Farmaceutici SpA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="16581">Grifols SA</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>5</CountTotal></Company><Company><Company id="17332">Johnson &amp; Johnson</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="10">Technology - Other Proprietary</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="110814" title="Bayer to utilize Inamed's AKITA technology worldwide for development and commercialization of AAT products"></Deal><Deal id="116515" title="Bayer divests Healthcare Biological Products business assets to Talecris"></Deal><Deal id="116516" title="Crucell to distribute Talecris's Prolastin in Europe"></Deal><Deal id="145112" title="Chiesi Farmaceutici to commercialize Grifols' Prolastin in Austria"></Deal><Deal id="156211" title="Alpha-1 Biologics to conduct clinical studies for Grifols' alpha-1 proteinase therapy for elevating CD4 counts  "></Deal><Deal id="246799" title="CHR and Talecris to provide clinical and administrative pharmacy services including Prolastin for alpha-1antitrypsin deficiency"></Deal></Deals><PatentFamilies><PatentFamily id="1014987" number="WO-00248176" title="Method of preparing alpha-1 proteinase inhibitor"></PatentFamily><PatentFamily id="1037610" number="WO-2011056793" title="Composition, method, and kit for α-1 proteinase inhibitor"></PatentFamily><PatentFamily id="1273731" number="US-04829054" title="Method Of Decreasing Lung Damage In A Host Following The Onset Of Gram Negative Septicemia/Endotoxemia"></PatentFamily><PatentFamily id="1557685" number="WO-2010009388" title="Method of preparing α-1 proteinase inhibitor"></PatentFamily><PatentFamily id="1575508" number="EP-00698615" title="Purification of alpha-1 proteinase inhibitor using novel chromatographic separation conditions."></PatentFamily><PatentFamily id="1780409" number="EP-02289540" title="Alpha-1-antitrypsin for use in the treatment of chronic fatigue syndrome"></PatentFamily><PatentFamily id="1843726" number="WO-2006108830" title="Transplastomic plants expressing α 1-antitrypsin"></PatentFamily><PatentFamily id="2015459" number="EP-00221426" title="Method Of Preparing Alpha-1-Proteinase Inhibitor"></PatentFamily><PatentFamily id="2458712" number="WO-2013011178" title="Rapid and accurate analysis of protein sialylation"></PatentFamily><PatentFamily id="309205" number="EP-00097274" title="Method For Separating Alpha-1-Proteinase Inhibitor From Blood Plasma Fractions"></PatentFamily><PatentFamily id="529127" number="EP-00147761" title="Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer."></PatentFamily><PatentFamily id="674819" number="WO-2012038820" title="Immunochromatography devices, methods and kits"></PatentFamily><PatentFamily id="755811" number="EP-00288841" title="Method of preparing highly purified alpha-1-proteinase inhibitor"></PatentFamily><PatentFamily id="942965" number="WO-00006186" title="alpha-1 Proteinase inhibitor binding peptides."></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="1">Analyte</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>7</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bayer AG" id="14455"></CompanyLink><CountAsOwner>9</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>9</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Grifols SA" id="16581"></CompanyLink><CountAsOwner>11</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>11</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>